Literature DB >> 7882281

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators.

E R Fisher1, J Costantino, B Fisher, A S Palekar, C Redmond, E Mamounas.   

Abstract

BACKGROUND: Controversy exists concerning the natural history of ductal carcinoma in situ (DCIS) of the breast, including its pathologic expression and treatment. This controversy has been fostered largely by the retrospective nature and limited sample sizes of extant studies.
METHOD: Resolution of some of these issues was attempted by analyzing the pathologic features of 573 examples of DCIS obtained from a larger cohort of 790 women with DCIS enrolled in Protocol B-17 of the National Surgical Adjuvant Breast Project. This prospective randomized clinical trial was performed to assess the efficacy of local breast irradiation to reduce the incidence of second ipsilateral breast tumors (IBT) after lumpectomy.
RESULTS: Tumor and patient characteristics, including significantly less IBT for those treated by lumpectomy and irradiation than lumpectomy alone, were almost identical for the subset comprising this analysis and the total B-17 cohort reported previously. The presence of moderate/marked comedo necrosis, which was evaluated as an independent parameter rather than as a specific histologic type of DCIS and uncertain/involved lumpectomy margins were the only statistically significant independent predictors of IBT for patients treated by lumpectomy as well as irradiation. The latter markedly reduced the annual hazard rates for the IBT associated with these indicators.
CONCLUSIONS: Although not an endpoint of this study, the authors' findings suggest that the beneficial effect of irradiation in reducing IBT after lumpectomy for DCIS occurs with small (< 1.0 cm.) and larger lesions. Moderate/marked comedo necrosis and uncertain/involved lumpectomy margins represent independent predictors of IBT.

Entities:  

Mesh:

Year:  1995        PMID: 7882281     DOI: 10.1002/1097-0142(19950315)75:6<1310::aid-cncr2820750613>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Ductal carcinoma in situ of the breast.

Authors:  M J Silverstein
Journal:  BMJ       Date:  1998-09-12

2.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.

Authors:  C C Wykoff; N Beasley; P H Watson; L Campo; S K Chia; R English; J Pastorek; W S Sly; P Ratcliffe; A L Harris
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Biology, treatment, and outcome in very young and older women with DCIS.

Authors:  Rosalinda Alvarado; Sara A Lari; Robert E Roses; Benjamin D Smith; Wei Yang; Elizabeth A Mittendorf; Banu K Arun; Anthony Lucci; Gildy V Babiera; Jamie L Wagner; Abigail S Caudle; Funda Meric-Bernstam; Rosa F Hwang; Isabelle Bedrosian; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2012-05-24       Impact factor: 5.344

4.  Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ.

Authors:  Monica Morrow; Kimberly J Van Zee; Lawrence J Solin; Nehmat Houssami; Mariana Chavez-MacGregor; Jay R Harris; Janet Horton; Shelley Hwang; Peggy L Johnson; M Luke Marinovich; Stuart J Schnitt; Irene Wapnir; Meena S Moran
Journal:  Pract Radiat Oncol       Date:  2016-06-24

5.  Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: patterns of failure and 10-year results.

Authors:  L L Kestin; N S Goldstein; A A Martinez; M Rebner; M Balasubramaniam; R C Frazier; J T Register; J Pettinga; F A Vicini
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

6.  Unsupervised feature construction and knowledge extraction from genome-wide assays of breast cancer with denoising autoencoders.

Authors:  Jie Tan; Matthew Ung; Chao Cheng; Casey S Greene
Journal:  Pac Symp Biocomput       Date:  2015

7.  A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial.

Authors:  S E Pinder; C Duggan; I O Ellis; J Cuzick; J F Forbes; H Bishop; I S Fentiman; W D George
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

8.  Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.

Authors:  Elizabeth Shurell; Cristina Olcese; Sujata Patil; Beryl McCormick; Kimberly J Van Zee; Melissa L Pilewskie
Journal:  Cancer       Date:  2017-09-28       Impact factor: 6.860

Review 9.  Current management of ductal carcinoma in situ.

Authors:  A Barth; R J Brenner; A E Giuliano
Journal:  West J Med       Date:  1995-10

10.  Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting.

Authors:  Laurel A Habel; Ninah S Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Stuart J Schnitt; Laura C Collins; Ann M Geiger; Balaram Puligandla; Luana Acton; Charles P Quesenberry
Journal:  Breast Cancer Res       Date:  2009-11-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.